PP1 and PP2A antagonize TSA-induced Sp1 phosphorylation and p107 release. A, JAR or MCF-7 cells were overexpressed with PP2AC or PP1C expression plasmid, respectively, followed by treatment with or without TSA. Empty vector was the control. Whole cell lysates were IP with Sp1 antibody followed by IB using anti-phosphoserine antibody (p-Ser) or Sp1 antibody. B, ChIP assays of p107 association with the LHR gene promoter in TSA-treated or nontreated JAR (100 ng/ml) or MCF-7 cells (500 ng/ml) with co-transfection of empty vector, PP1C, or PP2AC expression plasmids. Results are expressed as the percentage of occupancy of p107 in the absence of treatment (100%) (JAR cells: *, +TSA (vector) versus -TSA (vector), p < 0.01; *, +TSA (PP2AC) versus -TSA (PP2AC), p < 0.01; •, +TSA (vector) versus +TSA (PP2AC), p < 0.01; *, MCF-7 cells: +TSA (vector) versus -TSA (vector), p < 0.01; *, +TSA (PP1C) versus -TSA PP1C, p < 0.01; •, +TSA (vector) versus + TSA (PP1C) p < 0.01. C, schematic representation of functional roles of PP1 and PP2A in TSA-induced LHR gene activation. The TSA-induced changes of the chromatin modification status at the LHR promoter favor the release of PP2A or PP1 from the promoter in JAR or MCF-7 cells, respectively. This in turn facilitates the Sp1 phosphorylation by PI3K/PKCζ, which triggers the dissociation of p107 from the promoter and the LHR gene activation.